Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction

Clinical Pharmacokinetics

Volumn 50, Issue 2, 2011, Pages 131-142

  Dong, Jennifer Q ^a   Salinger, David H ^a   Endres, Christopher J ^a   Gibbs, John P ^a   Hsu, Cheng Pang ^b   Stouch, Brian J ^b   Hurh, Eunju ^b   Gibbs, Megan A ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DACLIZUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; MONOCLONAL ANTIBODY 2; MONOCLONAL ANTIBODY 3; MONOCLONAL ANTIBODY 4; MONOCLONAL ANTIBODY 5; MONOCLONAL ANTIBODY 6; MONOCLONAL ANTIBODY A; MONOCLONAL ANTIBODY B; MONOCLONAL ANTIBODY C; MONOCLONAL ANTIBODY D; MONOCLONAL ANTIBODY E; MONOCLONAL ANTIBODY F; RITUXIMAB; UNCLASSIFIED DRUG;

ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; FIRST IN HUMAN STUDY; MAXIMUM PLASMA CONCENTRATION; POPULATION MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LINEAR MODELS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RESEARCH DESIGN; RETROSPECTIVE STUDIES;

EID: 78751499845     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11537430-000000000-00000     Document Type: Article

References (54)

1. Meibohm B. The role of pharmacokinetics and pharmacodynamics in the de- velopment of biotech drugs. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Weinheim: Wiley-VCH, 2006: 3-12.
2. Mascelli MA, Zhou H, Sweet R, et al. Molecular, biologic, and pharm- acokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 2007 May; 47 (5): 553-65.
3. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008 Nov; 84 (5): 548-58.
4. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 Sep 7; 355 (10): 1018-28.
5. Center for Drug Evaluation and Research, US FDA. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville (MD): FDA, 2005 Jul [online]. Available from URL: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm078932.pdf [Accessed 2010 Nov 9].
6. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-inhuman clinical trials with investigational medicinal products. London: European Medicines Agency, 2007 Jul 19 [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guide line/2009/09/WC500002988. pdf [Accessed 2010 Nov 9].
7. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 2007 Dec; 12 (23-24): 1018-24.
8. Agoram BM. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 2009 Feb; 67 (2): 153-60.
9. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal anti- bodies. Drug Discov Today 2007 Jul; 12 (13-14): 540-7.
10. Muller PY, Brennan FR. Safety assessment and dose selection for first- in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009 Mar; 85 (3): 247-58.
11. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and phar- macodynamics. J Pharm Sci 2004 Nov; 93 (11): 2645-68.
12. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies: mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007 Jan; 10 (1): 84-96.
13. Brambell F. The transimission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966; 2 (7473): 1087-93.
14. Ling J, Zhou H, Jiao Q, et al. Interspecies scaling of therapeutic monoclonal antibobies: initial look. J Clin Pharmacol 2009 Dec; 49 (12): 1382-402.
15. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003 Apr; 5 (2): 172-9.
16. Ponce R, Abad L, Amaravadi L, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009 Jul; 54 (2): 164-82.
17. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982 Apr; 10 (2): 201-27.
18. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary- comparative paradigm. Drug Metab Rev 1984; 15 (5-6): 1071-121.
19. Boxenbaum H, D'Souza RW. Interspecies pharmacokinetic scaling, biological design, and neoteny. In: Testa B, editor. Advances in drug research. London: Academic Press Limited, 1990: 139-96.
20. Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacologi- cal data from animals to humans. In: Testa B, editor. Advances in drug research. San Diego (CA): Academic Press, 1991: 1-116.
21. Mordenti J, Chen SA, Moore JA, et al. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991 Nov; 8 (11): 1351-9.
22. Grene-Lerouge NA, Bazin-Redureau MI, Debray M, et al. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 1996 May; 138 (1): 84-9.
23. Bazin-Redureau M, Pepin S, Hong G, et al. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol Appl Pharmacol 1998 Jun; 150 (2): 295-300.
24. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 2004 Jan; 93 (1): 177-85.
25. Kelley SK, Gelzleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006 Aug; 148 (8): 1116-23.
26. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, inter- species scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999 Jan; 288 (1): 371-8.
27. Duconge J, Fernandez-Sanchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allo-metric paradigm: is it really suitable? Biopharm Drug Dispos 2004 May; 25 (4): 177-86.
28. Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics ofbiotech drugs: principles and case studies in drug development. Weinheim: Wiley-VCH, 2006: 45-91.
29. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973 Oct; 1 (5): 435-61.
30. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986 Nov; 75 (11): 1028-40.
31. US FDA. Drug approval package: Avastin (bevacizumab). Summary basis of approval [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2004/STN-125085-Avastin.cfm [Accessed 2010 Nov 26].
32. Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and im- proved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991 Aug 15; 147 (4): 1352-9.
33. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cyno-molgus monkeys. J Pharmacol Exp Ther 2005 May; 313 (2): 578-85.
34. US FDA. Infliximab product approval information - licensing action: Re- micade. Summary basis of approval [online]. Available from URL: http:// www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDeveloped andApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm 093327.htm [Accessed 2010 Nov 26].
35. US FDA. Overview: Rituxan (rituximab). Summary basis of approval [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ index.cfm?fuseaction=Search.Overview&DrugName=RITUXAN&CFID= 51165734&CFTOKEN=c8cf74698099620-6129AB8A-B4E8-AA2F-738FF37 B5F9776F9 [Accessed 2010 Nov 26].
36. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005 Jul; 45 (7): 792-801.
37. IVIG HCA pharmacy protocol [online]. Available from URL: http://www. docstoc.com/docs/19660410/IVIG-PHARMACY-PROTOCOL [Accessed 2010 Dec 3].
38. Thurmann PA, Sonnenburg-Chatzopoulos C, Lissner R. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol 1995; 49 (3): 237-42.
39. Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005 Jan; 22 (1): 103-12.
40. Adolph EF. Quantitative relations in the physiological constitutions of mam- mals. Science 1949 Jun 10; 109 (2841): 579-85.
41. US FDA. Trastuzumab product approval information - licensing action 9/25/98: Herceptin. Summary basis of approval [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/ApprovalApplications/TherapeuticBiologicAp plications/ucm080591.htm [Accessed 2010 Nov 26].
42. US FDA. Drug approval package: Mylotarg (gemtuzumab ozogamicin) in- jection. Summary basis of approval [online]. Available from URL: http:// www.accessdata.fda.gov/drugsatfda-docs/nda/2000/21174-Mylotorg.cfm [Accessed 2010 Nov 26].
43. US FDA. Drug approval package: Vectibix panitumumab injectable. Summary basis of approval [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2006/125147s0000TOC.cfm [Accessed 2010 Nov 26].
44. Kagan L, Abraham AK, Harrold JM, et al. Interspecies scaling of receptor- mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 2010 May; 27 (5): 920-32.
45. Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target- mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008 Oct; 35 (5): 573-91.
46. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approx- imations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 2009 Jul; 5 (7): 803-12.
47. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti- tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009 Sep; 49 (9): 1056-70.
48. Sun YN, Lu JF, Joshi A, et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 2005 Apr; 45 (4): 468-76.
49. Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2010 Mar; 50 (3): 257-67.
50. Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/pharmacody- namic model of interferon-beta 1a in humans. Pharm Res 2002 Oct; 19 (10): 1537-43.
51. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit com- partment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007 Oct; 34 (5): 711-26.
52. Vugmeyster Y, Tian X, Szklut P,et al. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody innaive and Ascaris-challenged cynomolgus monkeys. Pharm Res 2009 Feb; 26 (2): 306-15.
53. Lowe PJ. Applying physiological and biochemical concepts to optimize bio- logical drug development. Clin Pharmacol Ther 2010 Apr; 87 (4): 492-6.
54. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009; 24 (1): 16-24